You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • SAT0177 The Combination of Serum Matrix Metalloproteinase-3 and C-Reactive Protein at 4 Weeks Predict High Continuation Rate in RA Patients with Adalimumab Therapy

Article info

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
SAT0177 The Combination of Serum Matrix Metalloproteinase-3 and C-Reactive Protein at 4 Weeks Predict High Continuation Rate in RA Patients with Adalimumab Therapy

Authors

Citation

Hattori Y, Kaneko A, Kida D on behalf of TBCR Study Group , et al
SAT0177 The Combination of Serum Matrix Metalloproteinase-3 and C-Reactive Protein at 4 Weeks Predict High Continuation Rate in RA Patients with Adalimumab Therapy
Annals of the Rheumatic Diseases 2015;74:718.

Publication history

  • First published June 9, 2015.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions